Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAFFRontier-1 Trial in Progress)

View Full Paper
Ask AI
Bookmark
Share

Authors

MDMichael DickinsonCCChan Y. CheahDTDonald E. Tsai

Discussion

Loading...

Member takes

Overview

Phase 1 trial assesses LY4152199's antitumor activity in relapsed B-cell malignancies, suggesting efficacy and safety in patients.

Key Points

  • To determine the safety, optimal biological dose, pharmacokinetics, and anticancer activity of LY4152199 in patients with treated B-cell malignancies.
  • Global, open-label, phase 1 trial
  • Dose escalation and expansion with IV/subcut administration
  • Enrollment of patients with relapsed/refractory B-cell malignancies
  • Patients achieving complete response will receive 15 cycles of LY4152199
  • Potential antitumor activity shown in preclinical models
  • Dose optimization planned for patients with de novo DLBCL

Cite This Study

Dickinson et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e587https://doi.org/10.1182/blood-2025-5524
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase 1 assessment of novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)2025
  2. 2PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease.2024 · 4 citations
  3. 3BAFFR-CAR T cells (PMB-CT01) demonstrate durable responses and manageable toxicities in relapsed/refractory B-cell lymphomas with prior CD19-directed therapy failure or CD19-negative disease2025
  4. 4Novel transposon BAFF CAR-T cells (LMY-920) for non-Hodgkin lymphoma (NHL).2026
  5. 5A phase 1 study of LY007, a novel anti-CD20 CAR-T cell therapy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.2024 · 4 citations